FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling.
Compass Pathways executives discussed pricing as the COMP360 NDA nears completion, and state cannabis regulators say the DEA still hasn’t answered their rescheduling questions.

